<DOC>
	<DOCNO>NCT00602576</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving temozolomide together sorafenib may kill tumor cell . PURPOSE : This randomized phase II trial study two different schedule temozolomide give together sorafenib compare well work treat patient metastatic unresectable melanoma .</brief_summary>
	<brief_title>Temozolomide Sorafenib Treating Patients With Metastatic Unresectable Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To measure progression-free survival patient metastatic unresectable melanoma brain metastasis prior treatment temozolomide ( TMZ ) treat sorafenib tosylate combination two different schedule ( extend daily dose vs standard dose ) TMZ . - To measure progression-free survival patient without brain metastasis prior treatment TMZ treat sorafenib combination extend daily dose TMZ . - To measure progression-free survival patient brain metastasis prior treatment TMZ treat sorafenib combination standard dose TMZ . - To estimate median time progression patient . - To quantify number percent patient stable disease 6 month treatment ( failure progress ) . - To choose optimal combination dose regimen study . Secondary - To estimate define objective response rate patient . - To characterize duration objective response patient . - To estimate incidence new symptomatic brain metastasis patient . - To measure overall survival patient . OUTLINE : This multicenter study . Patients stratify accord prior brain metastasis ( yes v ) prior treatment temozolomide ( TMZ ) ( yes v ) . Patients prior brain metastasis receive prior treatment TMZ randomize 1 2 treatment arm . These patient stratify accord prior treatment sorafenib tosylate ( yes v ) . Patients without prior brain metastasis receive prior treatment TMZ assign arm I . Patients prior brain metastasis receive prior treatment TMZ assign arm II . - Arm I : Patients receive oral sorafenib tosylate twice daily day -7 56 course 1 day 1-56 subsequent course . Patients also receive oral TMZ daily day 1-42 . - Arm II : Patients receive sorafenib tosylate arm I oral TMZ daily day 1-5 29-33 . In arm , course repeat every 8 week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm melanoma Metastatic unresectable disease Measurable disease RECIST criterion Cutaneous lesion measure least 1 cm consider measurable disease Brain metastases allow provided patient complete radiotherapy , radiotherapy clinically indicated time diagnosis , AND discontinue steroid prior study enrollment PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm³ Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 2.0 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN ( &lt; 3.0 time ULN Gilbert 's disease present ) AST ALT ≤ 2.5 time ULN ( ≤ 5.0 time ULN liver metastasis present ) INR ≤ 1.5 ( anticoagulation , baseline INR must &lt; 1.5 start anticoagulation ) PTT normal No concurrent malignancy , except basal cell squamous cell skin cancer , carcinoma situ cervix , ductal lobular carcinoma situ breast No concurrent serious illness include , limited , follow : Ongoing active infection require parenteral antibiotic Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication Peripheral vascular disease ≥ grade II within past year Psychiatric illness/social situation would limit compliance study requirement Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy Prior radiotherapy allow If radiotherapy administer lesion , must radiographic evidence progression lesion lesion constitute measurable disease include measure target lesion Prior temozolomide sorafenib tosylate allow At least 4 week since prior chemotherapy At least 4 week since prior active immunotherapy ( aldesleukin , interferon , sargramostim [ GMCSF ] , CTLA4 ) At least 4 week since prior concurrent investigational anticancer therapy ( except vaccine ) No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>